scholarly journals Variation in the vitamin D receptor gene, plasma 25-hydroxyvitamin D, and risk of premenstrual symptoms

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Alicia C. Jarosz ◽  
Daniel Noori ◽  
Tara Zeitoun ◽  
Bibiana Garcia-Bailo ◽  
Ahmed El-Sohemy
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Lower Risk ◽  
Receptor Gene ◽  
Health Study ◽  
Vitamin D Status ◽  
Premenstrual Symptoms ◽  
Single Nucleotide ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Abstract Background Vitamin D status has been associated with the presence and severity of several premenstrual symptoms (PMSx) in some, but not all studies. Inconsistencies among findings may be explained by unaccounted genetic variation in the vitamin D receptor (VDR). Objective To determine whether associations between vitamin D status and individual PMSx are influenced by VDR genotype. Methods Seven hundred sixteen women aged 20-29 years old from the Toronto Nutrigenomics and Health study provided plasma samples and completed a questionnaire on the presence and severity of 15 common PMSx. Plasma 25-hydroxyvitamin D (25(OH)D) concentration was measured and participants were categorized into sufficient (≥ 50 nmol/L) and insufficient (< 50 nmol/L) vitamin D status groups. DNA was obtained from blood samples to genotype for a common VDR single nucleotide variant, rs796858. Using logistic regression, odds of experiencing PMSx were compared between vitamin D-sufficient and insufficient women, stratified by genotype. Results Among CC homozygotes, insufficient vitamin D status was associated with higher odds of experiencing premenstrual fatigue (OR, 2.53; 95% CI, 1.40, 4.56) and nausea (OR, 2.44; 95% CI, 1.00, 5.95). Among TT homozygotes, insufficient vitamin D status was associated with lower odds of experiencing fatigue (OR, 0.44; 95% CI, 0.20, 0.97) and increased appetite (OR, 0.48; 95% CI, 0.22, 1.04). Insufficient vitamin D status was associated with higher odds of increased appetite in women with the CT genotype (OR, 1.78; 95% CI, 1.03, 3.07). VDR genotype modified the association between vitamin D status and the following PMSx: increased appetite (interaction p = 0.027), fatigue (interaction p = 0.016), and nausea (interaction p = 0.039). Conclusion We found evidence that VDR genotype may modify the association between 25(OH)D and some PMSx. Insufficient 25(OH)D was associated with a higher risk of premenstrual fatigue in those with the CC genotype, but lower risk in those with the TT genotype.

scholarly journals Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival

2016 ◽  
Vol 34 (24) ◽  
pp. 2899-2905 ◽  
Author(s):  
Chen Yuan ◽  
Zhi Rong Qian ◽  
Ana Babic ◽  
Vicente Morales-Oyarvide ◽  
Douglas A. Rubinson ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Vitamin D ◽  
Plasma Level ◽  
Vitamin D Receptor ◽  
Statistical Significance ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene ◽  
Single Nucleotide ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Purpose Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored. Patients and Methods We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relative insufficiency, 20 to < 30 ng/mL; sufficient ≥ 30 ng/mL) by using Cox proportional hazards regression models adjusted for age, cohort, race and ethnicity, smoking, diagnosis year, stage, and blood collection month. We also evaluated 30 tagging single-nucleotide polymorphisms in the vitamin D receptor gene, requiring P < .002 (0.05 divided by 30 genotyped variants) for statistical significance. Results Mean prediagnostic plasma level of 25(OH)D was 24.6 ng/mL, and 165 patients (33%) were vitamin D insufficient. Compared with patients with insufficient levels, multivariable-adjusted HRs for death were 0.79 (95% CI, 0.48 to 1.29) for patients with relative insufficiency and 0.66 (95% CI, 0.49 to 0.90) for patients with sufficient levels (P trend = .01). These results were unchanged after further adjustment for body mass index and history of diabetes (P trend = .02). The association was strongest among patients with blood collected within 5 years of diagnosis, with an HR of 0.58 (95% CI, 0.35 to 0.98) comparing patients with sufficient to patients with insufficient 25(OH)D levels. No single-nucleotide polymorphism at the vitamin D receptor gene met our corrected significance threshold of P < .002; rs7299460 was most strongly associated with survival (HR per minor allele, 0.80; 95% CI, 0.68 to 0.95; P = .01). Conclusion We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.

scholarly journals Correction to: Variation in the vitamin D receptor gene, plasma 25-hydroxyvitamin D, and risk of premenstrual symptoms

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Alicia C. Jarosz ◽  
Daniel Noori ◽  
Tara Zeitoun ◽  
Bibiana Garcia-Bailo ◽  
Ahmed El-Sohemy
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene ◽  
Premenstrual Symptoms ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts

2012 ◽  
Vol 108 (10) ◽  
pp. 1889-1896 ◽  
Author(s):  
Kimberly A. Bertrand ◽  
Edward Giovannucci ◽  
Yan Liu ◽  
Susan Malspeis ◽  
A. Heather Eliassen ◽  
...  
Keyword(s):  
Vitamin D ◽  
Prediction Models ◽  
Epidemiological Studies ◽  
Health Study ◽  
Control Analysis ◽  
Vitamin D Status ◽  
Blood Draw ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Hormone Use

Epidemiological and other evidence suggests that vitamin D may be protective against several chronic diseases. Assessing vitamin D status in epidemiological studies, however, is challenging given finite resources and limitations of commonly used approaches. Using multivariable linear regression, we derived predicted 25-hydroxyvitamin D (25(OH)D) scores based on known determinants of circulating 25(OH)D, including age, race, UV-B radiation flux at residence, dietary and supplementary vitamin D intakes, BMI, physical activity, alcohol intake, post-menopausal hormone use (women only) and season of blood draw, in three nationwide cohorts: the Nurses' Health Study, Nurses' Health Study II and the Health Professionals Follow-up Study. The model r2 for each cohort ranged from 0·25 to 0·33. We validated the prediction models in independent samples of participants from these studies. Mean measured 25(OH)D levels rose with increasing decile of predicted 25(OH)D score, such that the differences in mean measured 25(OH)D between the extreme deciles of predicted 25(OH)D were in the range 8·7–12·3 ng/ml. Substituting predicted 25(OH)D scores for measured 25(OH)D in a previously published case–control analysis of colorectal cancer yielded similar effect estimates with OR of approximately 0·8 for a 10 ng/ml difference in either plasma or predicted 25(OH)D. We conclude that these data provide reasonable evidence that a predicted 25(OH)D score is an acceptable marker for ranking individuals by long-term vitamin D status and may be particularly useful in research settings where biomarkers are not available for the majority of a study population.

Sign in / Sign up

Export Citation Format

Share Document